Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate
…, PPM Kooij, WH Bakker, J Lasher… - Journal of nuclear …, 2005 - Soc Nuclear Med
The kidneys are critical organs in peptide receptor radiation therapy (PRRT). Renal function
loss may become apparent many years after PRRT. We analyzed the time course of decline …
loss may become apparent many years after PRRT. We analyzed the time course of decline …
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
…, M Ogura, N Fukuhara, J Davis, J Lasher… - Blood …, 2020 - ashpublications.org
Because of high relapse rates with rituximab combinations, there is an unmet need for new
therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular …
therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular …
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study
…, O Serri, L Katznelson, J Lasher… - The Journal of …, 2014 - Wiley Online Library
Pasireotide (SOM230), a multireceptor‐targeted somatostatin analogue, has exhibited favorable
safety/tolerability in several clinical studies. A long‐acting‐release (LAR) formulation of …
safety/tolerability in several clinical studies. A long‐acting‐release (LAR) formulation of …
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A+ B study)
…, JM Zaucha, J Davis, J Lasher… - British Journal of …, 2021 - Wiley Online Library
The standard of care for indolent non‐Hodgkin lymphoma (iNHL) is rituximab, an anti‐CD20
antibody, with/without chemotherapy. However, multiple relapses are common in these …
antibody, with/without chemotherapy. However, multiple relapses are common in these …
[HTML][HTML] Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I …
…, G Shen, J Jiang, H Liu, K Hu, C Darstein, J Lasher… - Clinical Therapeutics, 2014 - Elsevier
Purpose The purpose of this study was to assess the pharmacokinetic (PK) properties and
safety of single and multiple doses of subcutaneous (SC) pasireotide and a single-dose …
safety of single and multiple doses of subcutaneous (SC) pasireotide and a single-dose …
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center …
S Petersenn, K Hu, M Maldonado, Y Zhang, J Lasher… - Clinical Therapeutics, 2012 - Elsevier
BACKGROUND: Pasireotide is a multireceptor-targeted somatostatin analogue with high
binding affinity for somatostatin receptor subtypes SST 1, 2, 3, and 5. OBJECTIVE: To evaluate …
binding affinity for somatostatin receptor subtypes SST 1, 2, 3, and 5. OBJECTIVE: To evaluate …
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results
…, R Liu, M Izquierdo, J Lasher… - American journal …, 2022 - pubmed.ncbi.nlm.nih.gov
… 8 , Janet Lasher …
25th Annual Undergraduate Juried Exhibition to Open in
J Lasher - 2013 - digitalcommons.winthrop.edu
… The opening reception will also celebrate MFA Thesis Exhibitions by art and design majors
Janet Lasher and Jonathan Hoffman. A separate opening reception is scheduled for 6:30 pm …
Janet Lasher and Jonathan Hoffman. A separate opening reception is scheduled for 6:30 pm …
[HTML][HTML] Results of the Primary Analysis of Complement A+ B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in …
…, MM Keating, J Zaucha, J Davis, J Lasher… - Blood, 2018 - Elsevier
Background: Despite a variety of treatment options, indolent non-Hodgkin's lymphoma (iNHL)
remains a largely incurable disease with patients experiencing multiple relapses. Both …
remains a largely incurable disease with patients experiencing multiple relapses. Both …
[CITATION][C] Behind the Scenes
J Lasher - Arts Education Policy Review, 1934 - search.proquest.com